Skip to main content
. Author manuscript; available in PMC: 2015 Jul 24.
Published in final edited form as: Clin Cancer Res. 2014 Nov 11;21(2):357–364. doi: 10.1158/1078-0432.CCR-14-1374

Figure 2.

Figure 2

PFS according to YAP1 signature in (A) all patients (n = 80), (B) patients with WT KRAS (n = 43), and (C) patients with mutant KRAS (n = 27) in cohort 5. KRAS mutation data were not available for 10 patients.